article thumbnail

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

PharmaShots

In 2019, Mallinckrodt entered into a collaboration agreement with Silence Therapeutics to develop and commercialize RNAi therapeutics to treat life-threatening unmet diseases. Through the 2019 agreement, Mallinckrodt received the exclusive worldwide license to Silence’s SLN500. R&D Expenditure: $85.1M

article thumbnail

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

pharmaphorum

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face. Launches, therefore, were happening.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Agile, Data-Driven Life Cycle Management for Continuous Manufacturing

ISPE

1 , 4 A Retrospective Journey In 2015, Vertex’s Orkambi was the first approved drug produced under a CM process for the treatment of cystic fibrosis. Vertex continued to invest in CM with two additional approved drugs—Symdeco/Symkevi in 2018 and Trikafta in 2019—with the same indication. 8 (November/December 2019):26–29.

article thumbnail

How Balancing Iron Levels Can Help Your Thyroid

The Thyroid Pharmacist

8] A more recent 2019 study looked at the levels of three important nutrients for thyroid health: iodine, iron, and selenium. [9] And as we’ve seen, even with supplementation, you need to address your root causes to prevent iron supply and demand challenges. Too much iron/ferritin can be a problem. However, when they added 1.5

article thumbnail

How Do Adaptogenic Herbs Benefit Hashimoto’s?

The Thyroid Pharmacist

Nikolai Lazarev defined adaptogens as “an agent that raises the body’s ability to resist stress by countering undesired stressors, whether physical, chemical, emotional, or biological.” The first case is outlined in a 2019 report by Roberto Vita and his research team, and published in Revista da Associação Médica Brasileira.